Natera, Inc. (NASDAQ:NTRA) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 394,000 shares of the medical research company's stock after selling 61,807 shares during the period. Renaissance Technologies LLC owned about 0.30% of Natera worth $62,370,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NTRA. Blue Trust Inc. raised its position in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its position in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the period. Principal Securities Inc. raised its stake in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Natera Trading Up 0.9 %

Shares of Natera stock traded up $1.35 on Monday, hitting $149.39. The stock had a trading volume of 612,154 shares, compared to its average volume of 1,394,321. The stock has a market cap of $20.20 billion, a price-to-earnings ratio of -84.88 and a beta of 1.80. The stock's 50-day simple moving average is $152.66 and its two-hundred day simple moving average is $152.24. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. Piper Sandler boosted their price objective on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Sanford C. Bernstein increased their price objective on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Finally, Barclays decreased their target price on Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average target price of $175.76.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Fesko sold 663 shares of the company's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now owns 156,044 shares in the company, valued at $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 325,922 shares of company stock valued at $51,603,664 in the last 90 days. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.